Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3) encodes the p55 gamma regulatory subunit of the class IA phosphoinositide 3-kinase (PI3K) enzyme complex[2][5]. It binds to the p110 catalytic subunit and activated protein tyrosine kinases via its SH2 domains, regulating PI3K lipid kinase activity that is essential for producing PIP3 at the plasma membrane in response to extracellular signals. PIK3R3 is involved in signaling pathways that control cell growth, proliferation, survival, and metabolism. It is upregulated in several cancers and promotes tumor cell proliferation, potentially through mechanisms partly independent of classical Akt pathway activation[4][6]. PIK3R3 may be a novel therapeutic target, particularly in cancers exhibiting dysregulated PI3K pathway signaling. However, no selective drugs currently target PIK3R3 as a single agent.
PI3K inhibitors prevent production of phosphatidylinositol-3,4,5-trisphosphate (PIP3), blocking downstream signaling important for cell survival and proliferation[3][4]. Knockdown or inhibition induces G0/G1 cell cycle arrest and reduces cell proliferation[4][6].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3).